8 recruiting, 5 active not recruiting, 2 completed. 10 Phase 1, 6 Phase 2, 3 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 4, Recruiting 4, Completed 2 |
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 700 | 2025-08-06 | 2026-10-14 |
| AZD5305 hADME in Patients With Advanced Solid Malignancies Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose) - Locally Advanced or Metastatic Solid Tumor | Phase 1 | Recruiting | AstraZeneca | 8 | 2025-04-02 | 2026-11-12 |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer | Phase 3 | Recruiting | AstraZeneca | 788 | 2024-08-01 | 2026-10-30 |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents Saruparib, Placebo, Abiraterone Acetate - Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1898 | 2023-11-21 | 2026-11-10 |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. Saruparib (AZD5305), Darolutamide, No Treatment - Prostate Cancer | Phase 1 | Completed | AstraZeneca | 113 | 2023-09-21 | 2026-06-30 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 622 | 2023-06-05 | 2026-10-05 |
| Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies AZD5305, Itraconazole - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 16 | 2022-11-07 | 2024-06-18 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 174 | 2022-06-02 | 2026-08-26 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 460 | 2021-10-18 | 2026-10-13 |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer | Phase 1 | Recruiting | University of Leeds | 200 | 2021-03-17 | 2025-12-19 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 702 | 2020-11-12 | 2026-09-21 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Recruiting | OHSU Knight Cancer Institute | 90 | 2019-08-01 | 2026-09-04 |
| Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab - Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | Phase 1 | Active not recruiting | AstraZeneca | 358 | 2014-10-31 | 2026-07-24 |
Prostatic Neoplasms (6) · Ovarian Neoplasms (4) · Endometrial Neoplasms (3) · Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
AstraZeneca (12) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1) · University of Leeds (1)
United Kingdom (12) · United States (12) · Australia (9) · Canada (7) · Japan (7) · South Korea (7) · Spain (7) · China (6) · Italy (6) · Hungary (5) · Poland (5) · Taiwan (5) · France (4) · Germany (4) · Netherlands (4)
Alastair Greystoke, MB ChB, MSc, PhD (1) · Anne C Chiang (1) · Arun Azad, MD (1) · Charles D Lopez (1) · Corinne Faivre-Finn, MD, PhD (1) · Funda Meric-Bernstam, MD (1) · Kim Nguyen Chi, MD (1) · Timothy Yap (1)
PMID 34904813, PMID 35929986, PMID 36446040, PMID 39392424, PMID 41917211, PMID 41979035, PMID 42816529
2023 (4), 2014 (1), U10CA180888 (1)